A retrospective pooled analysis of duloxetine safety in 23 983 subjects

Current Medical Research and Opinion

Volumn 23, Issue 1, 2007, Pages 175-184

  Gahimer, James ^a   Wernicke, Joachim ^a   Yalcin, Ilker ^a   Ossanna, Melissa J ^a   Wulster Radcliffe, Meghan ^a   Viktrup, Lars ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Diabetic peripheral neuropathic pain; Drug safety; Duloxetine; Fibromyalgia; Generalized anxiety disorder; Major depressive disorder; Stress urinary incontinence

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DULOXETINE; PLACEBO;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DIABETIC NEUROPATHY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FATIGUE; FEMALE; FIBROMYALGIA; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; HYPERHIDROSIS; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHIC PAIN; PERIPHERAL NEUROPATHY; PREVALENCE; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINARY TRACT INFECTION; VITAL SIGN; XEROSTOMIA;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANXIETY DISORDERS; DEPRESSIVE DISORDER, MAJOR; DIABETIC NEUROPATHIES; FEMALE; FIBROMYALGIA; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; THIOPHENES; UNITED STATES; URINARY INCONTINENCE, STRESS;

EID: 33846669702     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X162719     Document Type: Article

References (23)

1. Pitsikas N. Duloxetine Eli Lilly & Co. Curr Opin Investig Drugs 2000;1:116-21
2. Wong DT, Bymaster FP. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drug Res 2002;58:169-222
3. Basbaum AI, Fields HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 1984;7:309-38
4. Clark FM, Proudfit HK. The projections of noradrenergic neurons in the A5 catecholamine cell group to the spinal cord in the rat: anatomical evidence that A5 neurons modulate nociception. Brain Res 1993;616:200-10
5. Coderre TJ, Katz J. Peripheral and central hyperexcitability: differential signs and symptoms in persistent pain. Behav Brain Sci 1997;20:404-19
6. Thor KB, Hisamitsu T, de Groat WC. Unmasking of a neonatal somatovesical reflex in adult cats by the serotonin autoreceptor agonist 5-methoxy-N,N- dimethyltryptamine. Brain Research 1990;54:35-42
7. Espey MJ, Downie JW, Fine A. Effect of 5-HT receptor and adrenoceptor antagonists on micturition in conscious cats. Eur J Pharmacol 1992;221:167-70
8. Danuser H, Thor KB. Spinal 5-HT2 receptor-mediated facilitation of pudendal nerve reflexes in the anaesthetized cat. Br J Pharmacol 1996;118:150-4
9. Krier J, Thor KB, de Groat WC. Effects of clonidine on the lumbar sympathetic pathways to the large intestine and urinary bladder of the cat. Eur J Pharmacol 1979;59:47-53
10. Pedersen E, Torring J, Klemar B. Effect of the alpha-adrenergic blocking agent thymoxamine on the neurogenic bladder and urethra. Acta Neurol Scand 1980;61:107-14
11. Gajewski J, Downie JW, Awad SA. Experimental evidence for a central nervous system site of action in the effect of alpha-adrenergic blockers on the external urinary sphincter. J Urol 1984;132:403-9
12. Downie JW, Bialik GJ. Evidence for a spinal site of action of clonidine on somatic and viscerosomatic reflex activity evoked on the pudendal nerve in cats. J Pharmacol Exp Ther 1988;246:352-8
13. Downie JW, Espey MJ, Gajewski JB. Alpha 2-adrenoceptors not imidazole receptors mediate depression of a sacral spinal reflex in the cat. Eur J Pharmacol 1991;195:301-4
14. Hurley D, Turner CL, Yalcin I, Viktrup L, et al. Duloxetine for the treatment of stress urinary incontinence in women: an integrated analysis of safety. Eur J Obstet Gynecol Reprod Biol 2006;125:120-8
15. Raskin J, Pritchett YL, Wang F, D'Souza DN, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-56
16. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15
17. Hudson JI, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, et al. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol 2005;20:327-41
18. Cymbalta [package insert]. Indianapolis, IN, USA. Eli Lilly & Company, 2005
19. Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 1999;20:277-87
20. Bump R, Yalcin I, Voss S. The effect of duloxetine dose escalation and tapering on the incidence of adverse events (AE) in women with stress urinary incontinence. Neurourol Urodyn 2005;24:116
21. Dunner DL, Wohlreich MM, Mallinckrodt CH, Watkin JG, et al. Clinical consequences of initial duloxetine dosing strategies: comparison of 30 and 60 mg QD starting doses. Curr Ther Res 2005;66:1-19
22. Navarro VJ, Senior JR. Drug-Related Hepatotoxicity. N Engl J Med 2006;354:731-9
23. Acharya N, Rosen AS, Polzer JP, D'Souza DN, et al. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol 2006;26:587-94